DMD/2013/052092 Introduction
MicroRNAs (miRNAs or miRs) are a large family of short (~22 nt), single strand non-coding RNAs transcribed from genome. miRNAs usually suppress target gene expression through the inhibition of translation or acceleration of mRNA degradation after imperfectly complementary Watson-Crick base pairings with miRNA response element (MRE) within the 3'-untranslated regions (3'UTRs) of mRNA targets. Over 2,000 miRNAs have been identified in humans, and they are predicted to govern posttranscriptional regulation of thousands of protein coding genes in control of essentially all life processes (Kasinski and Slack, 2011) . Nevertheless, there are only a limited number of studies (Tsuchiya et al., 2006; Kovalchuk et al., 2008; To et al., 2008; Pan et al., 2009a; Pan et al., 2009b; Liang et al., 2010; Mohri et al., 2010; Haenisch et al., 2011; Li et al., 2011; Borel et al., 2012) on miRNA-controlled posttranscriptional gene regulation of xenobiotic metabolizing enzymes and transporters underlying drug metabolism and disposition as well as multidrug resistance (MDR).
ATP-binding cassette, sub-family C (CFTR/MRP), member 1 (ABCC1/MRP1) is a membrane transporter expressed ubiquitously in human tissues, and contributes to cellular disposition of a large number of xenobiotics (e.g., doxorubicin, SN-38 and imatinib) and endobiotics (e.g., glutathione and leukotrienes). Inhibition, genetic variations and altered expression of ABCC1 may lead to variable drug disposition, cytotoxicity and clinical outcome (Maeno et al., 2009; Cho et al., 2011; Pajic et al., 2011) . ABCC1 is also able to confer the resistance to many chemotherapeutic agents such as anthracyclines (e.g., doxorubicin) and folate antagonist methotrexate. Indeed, clinical studies have demonstrated that overexpression of ABCC1 in a This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on May 16, 2013 as DOI: 10.1124 at ASPET Journals on July 7, 2017 dmd.aspetjournals.org Downloaded from variety of solid or invasive tumors such as breast, ovarian, lung, prostate and neuroblastoma is implicated as a high risk factor of MDR and a negative prognostic biomarker (Filipits et al., 2005; Haber et al., 2006; Triller et al., 2006; Faggad et al., 2009) . As an example, ABCC1 is readily detectable in all primary neuroblastoma samples studied, and a greater degree of ABCC1 expression is highly predictive of both event-free survival and overall survival of the patients (Haber et al., 2006) .
The 3'UTR of ABCC1 is around 2 kb in length, and it contains a number of computationally predicted MREs that awaits experimental investigation. Recently, the action of miR-326 on ABCC1 3'UTR and impact on ABCC1-mediated MDR has been successfully demonstrated (Liang et al., 2010) . Understanding the miRNA-controlled epigenetic regulatory mechanisms shall provide novel insight into interindividual variability in drug absorption, distribution, metabolism and excretion (ADME) as well as overexpression of ABC efflux transporters in MDR cancer cells towards the development of rational or new drug therapy (Gomez and Ingelman-Sundberg, 2009; Yu, 2009; Ingelman-Sundberg and Gomez, 2010; Nakajima and Yokoi, 2011; Yu and Pan, 2012; Yokoi and Nakajima, 2013) . Therefore, we aimed to delineate the action of a relatively newer human miRNA hsa-miR-1291 on the 3'UTR of ABCC1 in present study. Interestingly, we find that hsa-miR-1291 sequences reside within the small nucleolar RNA (snoRNA), H/ACA box 34 (SNORA34) (Watkins and Bohnsack, 2012) . We show that SNORA34 indeed can be processed to mature hsa-miR-1291 in PANC-1 cells.
Furthermore, we present data suggesting that hsa-miR-1291 regulates ABCC1 gene expression, and the suppression of ABCC1 protein expression by hsa-miR-1291 is translated into a significantly greater level of intracellular drug accumulation and chemosensitivity. This article has not been copyedited and formatted. The final version may differ from this version. Luciferase Reporter Assay. The luciferase reporter assay was performed as described previously (Pan et al., 2009a; Pan et al., 2009b μ g/mL of G418. After 3-5 weeks, G418-resistant clones were selected with a cloning ring for amplification in culture.
Splinted Ligation. The splinted ligation was conducted as described (Maroney et al., 2008 ) with some modifications. Briefly, total RNA was isolated with Trizol reagent, and quantified using NanoDrop (Thermo Scientific, Rockford, IL). 500 ng of total RNA was mixed with 100 fmol of bridge oligonucleotides and 2 pmol of 3'-digoxin-labeled ligation oligonucleotides (Table 1) 
Reverse Transcription (RT)-Quantitative Real-Time PCR (qPCR). RT-qPCR quantification
of mRNA of interest and stem loop RT-qPCR analyses of mature hsa-miR-1291 were conducted using gene selective primers (Table 1) on Bio-Rad MyIQ real-time PCR system, as described Rodrigues et al., 2011) . The cycle number (C T ) at which the amplicon concentration crossed a defined threshold was determined for each mRNA/miRNA. The relative level of each analyte over internal standard was calculated using the formula 2 -ΔC T , where ΔC T was the difference in C T values between analyte and internal standard (18S or U74), and then compared between different groups or treatments. Membranes were incubated with selective antibody against ABCC1 or GAPDH, and subsequently with a peroxidase goat anti-mouse IgG. The membranes were then incubated with ECL substrates, and images were acquired by ChemiDoc XRS+ System (Bio-Rad).
RNA Degradation
Flow Cytometry Analyses. Intracellular drug accumulation was investigated using a FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ), as reported . Chemosensitivity. Cell sensitivity to doxorubicin was carried out as described (Pan et al., 2009a 
Results
Mature hsa-miR-1291 is derived from SNORA34. To improve the understanding of miRNA mechanistic functions in regulation of ADME, we employed multiple bioinformatic algorithms to screen potential miRNA targets for cytochrome P450 enzymes and ABC transporters. To identify more promising miRNA candidates, we conducted analyses to see if particular miRNAs were enriched for a list of ADME 106 genes by comparing the number of miRNA target ADME genes to the number of genes for the same miRNA in the whole human genome (unpublished data).
Candidate miRNAs showing significant enrichment (Fisher's exact test) were obtained for further analysis. Among a set of putative miRNAs (unpublished data), hsa-miR-1291 is a newer miRNA that might be generated from SNORA34 ( Fig. 1 and 2 ) and act on the 3'UTR of ABCC1 (Fig. 3 ) critical for xenobiotic disposition and MDR. Thus we examined the biogenesis of hsa-miR-1291 and possible role in regulation of ABCC1-mediated drug disposition.
Our bioinformatic analyses also showed that hsa-miR-1291 sequences are located within the intron 9 of an uncharacterized gene C12orf41 on human chromosome 12q13.11. Given the fact that the precursor hsa-mir-1291 overlaps with SNORNA34 ( Fig. 1) , we reasoned that SNORA34 might be processed to 24-nt mature hsa-miR-1291. To test the hypothesis, a splinted ligation method based on a direct ligation of miRNA and probe (Maroney et al., 2008) was adapted to examine the association of SNORA34 and hsa-miR-1291 expression in PANC-1, H69AR, and H69 cells using a non-radioactive digoxin labeled probe with relative high sensitivity, among which PANC-1 and drug resistant H69AR cells exhibit high level expression of ABCC1. Our data showed that SNORA34 was detectable from the total RNAs isolated from PANC-1, H69AR, This article has not been copyedited and formatted. The final version may differ from this version. and H69 cells ( Fig. 2A) . Among them, H69 cells exhibited the lowest level of SNORA34, and PANC-1 cells had the highest level. Consistent with this finding, miR-1291 showed a greater expression in PANC-1 cells whereas it was undetectable in H69 cells ( Fig. 2A) , suggesting a positive relationship between hsa-miR-1291 and SNORA34 expression.
To investigate the processing of SNORA34, we created a SNORA34/miRNA-1291 expression plasmid. A 1033-bp fragment of SNORA34 was inserted into the intron 2 of globin within the snoRNA expression vector pCMV-globin to maintain the intronic feature of SNORA34. This design also proved to ensure a good expression of snoRNA Kiss et al., 2002) . After a transient transfection with SNORA34 expression plasmids, the expression of SNORA34 was increased in H69AR cells but unchanged in PANC-1 cells (Fig. 2B) . However, hsa-miR-1291 expression level remained undetectable in SNORA34 transfected H69AR cells, whereas it seemed to be higher in SNORA34 transfected PANC-1 cells (Fig. 2B) , suggesting a fine processing of SNORA34 to hsa-miR1291 in PANC-1 cells. Therefore, the PANC-1 cells were further transfected with an anti-miR-1291 oligonucleotide. As expected, the expression of mature hsa-miR-1291 was markedly reduced by the hsa-miR-1291 antagomir (Fig. 2B) . The results suggest that mature hsa-miR-1291 may be generated from SNORA34 in PANC-1 cells.
hsa-miR-1291 acts on the 3'UTR of ABCC1. The ABCC1 3'UTR consists of four putative hsa-miR-1291 MRE sites (Fig. 3A) . The first site (position 32-38) is well conserved, and the others are relatively more selective for human ABCC1. in cells transfected with anti-miR-1291 oligonucleotide (Fig. 3B) . These data support the actions of hsa-miR-1291 on the 3'UTR of ABCC1.
hsa-miR-1291 regulates the expression of ABCC1. To examine the potential role of hsa-miR-1291 in regulation of ABCC1, we first generated a SNORA34/hsa-miR-1291 stably transfected PANC-1 cell line (Fig. 4) . Quantitative PCR analyses showed that hsa-miR-1291
expression was approximately 18-fold higher in SNORA34/hsa-miR-1291 stably transfected PANC-1 cells than the control, whereas SNORA34 expression was unchanged (Fig. 4) .
Overexpression of hsa-miR-1291 led to a reduced ABCC1 protein expression in hsa-miR-1291 stably transfected cells, as revealed by immunoblot analyses (Fig. 5A ). This was associated with a ~5-fold lower ABCC1 mRNA expression (data not shown). Furthermore, the suppression of ABCC1 protein expression by gain of hsa-miR-1291 function could be rescued, as manifested by the increase of ABCC1 protein expression in hsa-miR-1291 stably transfected cells after transient transfection with anti-miR-1291 oligonucleotide (Fig. 5B ) that was associated with a ~11-fold higher ABCC1 mRNA expression (data not shown).
In addition, an mRNA degradation study was performed to test if mRNA decay mechanism was involved in the hsa-miR-1291 controlled posttranscriptional regulation of ABCC1. When actinomycin D blocked de novo RNA synthesis, ABCC1 mRNA stability did not differ between cells transfected with hsa-miR-1291 and control plasmids (Fig. 6 ). This might exclude the This article has not been copyedited and formatted. The final version may differ from this version. hsa-miR-1291 modulates cellular drug disposition. To examine whether the regulation of ABCC1 protein expression by hsa-miR-1291 can be translated into significant difference in xenobiotic disposition, flow cytometry analyses was conducted to determine intracellular doxorubicin accumulation. Our data showed that there was a greater level of doxorubicin fluorescence intensity in hsa-miR-1291 stably transfected PANC-1 cells (Fig. 7A) . Overall, doxorubicin accumulated within hsa-miR-1291 stably transfected PANC-1 cells was ~2.5-fold higher than the control cells (Fig. 7B) , which is likely due to a lower ABCC1 expression (Fig. 5A) that is able to pump the anti-neoplastic drug doxorubicin out of the cells.
Gain of hsa-miR-1291 function sensitizes human carcinoma cells to xenobiotics.
To evaluate the impact of hsa-miR-1291 controlled regulation of ABCC1 on chemosensitivity, the MTT assay was employed to define the cytotoxicity of doxorubicin in PANC-1 cells stably transfected with hsa-miR-1291 and control plasmids. Cytotoxicity was measured after 48 h treatment with various concentrations of doxorubicin. The data showed that hsa-miR-1291 stably transfected cells were much more sensitive to doxorubicin (Fig. 8) . This was also demonstrated by a significantly lower IC50 value (137 ± 1 μM) and steeper Hill slope (-1.08 ± 0.13) in hsa-miR-1291 transfected cells than the control cells (373 ± 2 μM and -0.50 ± 0.05, respectively).
The results indicate that gain of hsa-miR-1291 function sensitizes PANC-1 cells to doxorubicin.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
There is increasing evidence supporting that noncoding miRNAs may contribute to epigenetic regulation of ADME processes through their actions on xenobiotic metabolizing enzymes, transporter and nuclear receptors (Gomez and Ingelman-Sundberg, 2009; Yu, 2009; Ingelman-Sundberg and Gomez, 2010; Nakajima and Yokoi, 2011; Yu and Pan, 2012; Yokoi and Nakajima, 2013) . In this study, we demonstrate that snoRNA-derived hsa-miR-1291 targets the 3'UTR of membrane transporter ABCC1, and negatively regulates the expression of ABCC1.
Gain of hsa-miR-1291 function can sensitize carcinoma cells to anticancer drug via increasing ABCC1-mediated intracellular drug accumulation.
The snoRNAs are another class of non-coding regulatory RNAs that are 60-300 nt in length, and mainly responsible for the posttranscriptional modification of ribosomal RNAs in cells (Kiss, 2002; Watkins and Bohnsack, 2012 ). There are two major groups of snoRNAs, box C/D snoRNAs and box H/ACA snoRNAs, which function as guide RNAs for the 2'-O-methylation and pseudouridylation of target RNA sequences, respectively. Most interestingly, evolutionarily conserved box H/ACA snoRNAs share structural similarities with miRNA precursors. Consisting of two hairpin domains, H/ACA snoRNAs can be processed by the RNase III-type endoribonuclease Dicer to produce mature miRNAs (Scott et al., 2009) or miRNA-like small RNAs (Ender et al., 2008; Saraiya and Wang, 2008) . Recent studies have also demonstrated the derivation of small RNAs from box C/D snoRNAs, which exhibit miRNA-like functions (Brameier et al., 2011) . The hsa-miR-1291 precursor (Fig. 1) has been shown to structurally resemble an H/ACA snoRNA, SNORA34 (Scott et al., 2009 ). In the present study, we show the This article has not been copyedited and formatted. The final version may differ from this version. The processing of SNORA34 to hsa-miR-1291 might be tissue or cell type dependent. The hsa-miR-1291 was original discovered via massively parallel sequencing of small RNA libraries generated from stem cells (Morin et al., 2008) , and SNORA34 was cloned from HeLa cells (Kiss et al., 2004) . We first identified and cloned hsa-miR-1291 sequences from LS-180 cells (unpublished data) when studying miRNA-controlled regulation of CYP3A4 (Pan et al., 2009a) .
Our recent report showed a lower expression of hsa-miR-1291 than some other ADME regulatory miRNAs in MCF-7 and Caco-2 cells, which might be altered by xenobiotics (Rodrigues et al., 2011) . Current study revealed that hsa-miR-1291 was undetectable in H69 cells, which was associated with a lower level of SNORA34. In contrast, both SNORA34 and hsa-miR-1291 were found to be present at a higher level in PANC-1 cells (Fig. 2) . These observations suggest a cell specific biogenesis of hsa-miR-1291, and the underlying machinery awaits further exploration.
This article has not been copyedited and formatted. The final version may differ from this version. Computational identification of putative MRE sites for hsa-miR-1291 within ABCC1 3'UTR ( Fig. 3) led to the findings on hsa-miR-1291-controlled suppression of ABCC1 mRNA and protein expression (Fig. 5) . While mRNA degradation study suggests that hsa-miR-1291 does not change ABCC1 mRNA stability, the experiment might be complicated by the fact that actinomycin D is also a substrate of ABCC1 (Hill et al., 2013) . Additional investigations are needed to determine whether hsa-miR-1291-mediated suppression of ABCC1 indeed involves translation inhibition. In addition, because there is a lack of hsa-miR-1291 MRE within ABCC1
5'UTR, hsa-miR-1291 might affect ABCC1 expression through the targeting of its transcription factor. Nevertheless, the importance of miRNA regulatory mechanisms is nicely exemplified by its significant impact on ABCC1-mediated cellular drug disposition and chemosensitivity . Recent studies have also revealed a critical role for miR-134 and miR-326 in regulation of ABCC1 and the association with MDR (Guo et al., 2010; Liang et al., 2010) . Other examples of miRNA functions in regulation of ABC transporters include the control of ABCB1 expression by miR-451 and miR-27 (Kovalchuk et al., 2008; Zhu et al., 2008) , ABCG2 by miR-328, miR-519c
and miR-520h Pan et al., 2009b; Wang et al., 2010; Li et al., 2011) , and ABCC2
by miR-379 (Haenisch et al., 2011) . These findings support the importance of regulatory miRNAs in modulation of cellular ADME processes and potential influence on pharmacokinetics and pharmacodynamics (Gomez and Ingelman-Sundberg, 2009; Yu, 2009; Ingelman-Sundberg and Gomez, 2010; Nakajima and Yokoi, 2011; Yu and Pan, 2012; Yokoi and Nakajima, 2013) .
Overexpression of ABCC1 is frequently observed in MDR cancers and closely related to the outcome of chemotherapy (Filipits et al., 2005; Haber et al., 2006; Faggad et al., 2009) hsa-miR-1291 is significantly downregulated in human pancreatic ductal adenocarcinoma, compared to normal pancreas (unpublished data). Very recent studies also show a lower expression of hsa-miR-1291 in acute myocardial infarction (Meder et al., 2011) and renal cell carcinoma (Hidaka et al., 2012) , suggesting a common downregulation of hsa-miR-1291 in cancerous tissues. Given the finding on hsa-miR-1291-mediated suppression of ABCC1, novel approaches might be developed to intervention of hsa-miR-1291 pathways towards combating MDR. Nevertheless, the clinical significance of hsa-miR-1291 warrants additional critical studies.
In summary, our results indicate that SNORA34 may serve as a hsa-miR-1291 precursor. Our data also show that hsa-miR-1291 targets the 3'UTR of ABCC1, and consequently regulates the expression of ABCC1. The impact of hsa-miR-1291 on ABCC1-mediated drug disposition and chemosensitivity support our hypothesis that interference of miRNA regulatory pathway can sensitize human carcinoma cells to anticancer drugs. An improved understanding of miRNA functions in control of ABC transporters as well as miRNA biogenesis will not only provide new insights into variable drug disposition but also offer novel clue to develop rational drug therapy and combat MDR.
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